Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Crinetics Pharmaceuticals, Inc. (CRNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-1study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 Development of CRN04777 Suspended Company Hosting KOL Webinar on Acromegaly Treatment Landscape Today at 12:00 pm ET SAN DIEGO – August 8, 2023 – Crinetics Pharmaceuticals, Inc."
07/13/2023 144 Form 144 - Report of proposed sale of securities:
07/12/2023 144 Form 144 - Report of proposed sale of securities:
07/11/2023 144 Form 144 - Report of proposed sale of securities:
06/16/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 8-K Other Events  Interactive Data
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Paltusotine’s Phase 3 PATHFNDR-1study enrollment complete and topline data expected in 3Q 2023 - Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 - Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024 - Paltusotine’s Phase 2 study in carcinoid syndrome on track for data in 2H 2023 - CRN04894’s studies in Cushing’s disease and congenital adrenal hyperplasia commenced in 1Q 2023 SAN DIEGO – February 28, 2023"
02/14/2023 SC 13G/A ORBIMED ADVISORS LLC reports a 5.9% stake in Crinetics Pharmaceuticals Inc.
02/14/2023 SC 13G BRAIDWELL LP reports a 6.4% stake in CRINETICS PHARMACEUTICALS INC
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 5.1% stake in Crinetics Pharmaceuticals, Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 SC 13G/A DRIEHAUS CAPITAL MANAGEMENT LLC reports a 10.4% stake in Crinetics Pharmaceuticals, Inc.
02/06/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.3% stake in Crinetics Pharmaceuticals, Inc.
01/27/2023 5 Wilson Marc (CFO) has filed a Form 5 on Crinetics Pharmaceuticals, Inc.
01/27/2023 5 Krasner Alan Seth (Chief Medical Officer) has filed a Form 5 on Crinetics Pharmaceuticals, Inc.
01/27/2023 5 Knight Jeff E. (COO) has filed a Form 5 on Crinetics Pharmaceuticals, Inc.
01/09/2023 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/14/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
10/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Enrollment Completed in Phase 3 PATHFNDR-1study Evaluating Oral Paltusotine for the Treatment of Acromegaly Topline results for PATHFNDR-1study expected in Q3 2023 SAN DIEGO – October 13, 2022 – Crinetics Pharmaceuticals, Inc."
10/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer SAN DIEGO, October 3, 2022 -- Crinetics Pharmaceuticals, Inc."
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenital Adrenal Hyperplasia CRN04777 and CRN04894 Phase 2 Studies Expected to Commence Following Finalization of Study Protocols with Global Regulators SAN DIEGO – August 12, 2022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy